SBT-6290

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSBT-6290
Drug Alias NameSBT-6290
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionToll like receptor 8 agonistsAnti-NECTIN4
TargetsToll like receptor 8Nectin-4
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsBreast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSilverback Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSilverback Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungTriple Negative Breast NeoplasmsBreast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A